OBJECTIVE： To observe the clinical efficacy of foscarnet sodium combined with recombinant human interferon α2b in the treatment of persistent infection of cervical HPV. METHODS： A total of 65 patients infected with HPV were enrolled in the study and divided into treatment group （n＝35） and control group （n＝30）. Both groups were treated with recombinant human interferon α2b 100 000 IU， qod （at bedtime）， for 3 months； treatment group was additionally treated with Foscarnet chloride and sodium chloride injection 250 mL， ivgtt， qd， for 14 d. Therapeutic efficacy based on HPV viral loading amount， negative rate of HPV and cervicitis score were observed in 2 groups as well as therapeutic efficacy based on cervicitis score improvement rate and the occurrence of ADR. RESULTS： Total effective rate based on HPV viral loading amount of treatment group （94.29％） was significantly higher than that of control group （76.67％）， with statistical significance （P＜0.05）. The negative rate of HPV in treatment group （77.14％） was significantly higher than in control group （36.67％）， with statistical significance （P＜0.05）.The cervicitis scores of 2 groups were decreased significantly compared to before treatment， the treatment group [（1.49±0.70）score] was significantly lower than the control group [（1.97±0.89）score]， with statistical significance （P＜0.05）. The total effective rate based on improvement rate of cervicitis scores of treatment groups （88.57％） was significantly higher than that of control group （73.33％）， with statistical significance （P＜0.05）. No ADR was found in 2 groups during treatment. CONCLUSIONS： Foscarnet sodium combined with recombinant human interferon α2b can effectively inhibit HPV virus， improve the negative rate of HPV， and also relieve the cervicitis with good safety.